The amplification of CCND1 and the deletion of CDKN2A/2B, together with TP53 mutations, may play pivotal roles in ESCC by deregulating G1 cell cycle signaling, which classify this cancer into different groups. The gene discussed is CDKN2A; the disease is esophageal squamous cell carcinoma.